Eli Lilly and Company - Asset Resilience Ratio

Latest as of September 2025: 8.63%

Eli Lilly and Company (LILY34) has an Asset Resilience Ratio of 8.63% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

R$9.91 Billion

≈ $1.95 Billion USD Cash + Short-term Investments

Total Assets

R$114.94 Billion

≈ $22.55 Billion USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2014–2024)

This chart shows how Eli Lilly and Company's Asset Resilience Ratio has changed over time. Check LILY34 PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Eli Lilly and Company's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see LILY34 company net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	R$9.79 Billion	8.52%
Short-term Investments	R$121.60 Million	0.11%
Total Liquid Assets	R$9.91 Billion	8.63%

Asset Resilience Insights

Limited Liquidity: Eli Lilly and Company maintains only 8.63% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Eli Lilly and Company Industry Peers by Asset Resilience Ratio

Compare Eli Lilly and Company's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Merck & Company Inc NYSE:MRK	Drug Manufacturers - General	0.29%
AbbVie Inc NYSE:ABBV	Drug Manufacturers - General	0.02%
AstraZeneca PLC NASDAQ:AZN	Drug Manufacturers - General	0.10%
Novartis AG SW:NOVN	Drug Manufacturers - General	0.08%
Novo Nordisk A/S CO:NOVO-B	Drug Manufacturers - General	0.09%
Pfizer Inc SA:PFIZ34	Drug Manufacturers - General	5.48%
AstraZeneca PLC LSE:AZN	Drug Manufacturers - General	0.10%
Aurora Optoelectronics Co Ltd SHG:600666	Drug Manufacturers - General	5.89%

Annual Asset Resilience Ratio for Eli Lilly and Company (2014–2024)

The table below shows the annual Asset Resilience Ratio data for Eli Lilly and Company.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	4.35%	R$3.42 Billion ≈ $671.69 Million	R$78.71 Billion ≈ $15.45 Billion	-0.23pp
2023-12-31	4.57%	R$2.93 Billion ≈ $574.47 Million	R$64.01 Billion ≈ $12.56 Billion	+0.10pp
2022-12-31	4.47%	R$2.21 Billion ≈ $434.00 Million	R$49.49 Billion ≈ $9.71 Billion	-3.54pp
2021-12-31	8.01%	R$3.91 Billion ≈ $766.94 Million	R$48.81 Billion ≈ $9.58 Billion	+0.11pp
2020-12-31	7.89%	R$3.68 Billion ≈ $722.34 Million	R$46.63 Billion ≈ $9.15 Billion	+7.64pp
2019-12-31	0.26%	R$101.00 Million ≈ $19.82 Million	R$39.29 Billion ≈ $7.71 Billion	+0.06pp
2018-12-31	0.20%	R$88.20 Million ≈ $17.31 Million	R$43.91 Billion ≈ $8.62 Billion	-3.13pp
2017-12-31	3.33%	R$1.50 Billion ≈ $293.92 Million	R$44.98 Billion ≈ $8.83 Billion	-0.42pp
2016-12-31	3.75%	R$1.46 Billion ≈ $285.79 Million	R$38.81 Billion ≈ $7.61 Billion	+1.55pp
2015-12-31	2.21%	R$785.40 Million ≈ $154.11 Million	R$35.57 Billion ≈ $6.98 Billion	-0.42pp
2014-12-31	2.63%	R$955.40 Million ≈ $187.47 Million	R$36.31 Billion ≈ $7.12 Billion	--

pp = percentage points

About Eli Lilly and Company

SA:LILY34 Brazil Drug Manufacturers - General

Market Cap

$853.51 Billion

R$4.35 Trillion BRL

Market Cap Rank

#17 Global

#3 in Brazil

Share Price

R$153.70

Change (1 day)

+0.70%

52-Week Range

R$114.19 - R$200.21

All Time High

R$200.21